Equibles does not estimate personal net worth.
Get an email with a short summary when Recursion Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get RXRX alertsChris Gibson is recorded as CEO at Recursion Pharmaceuticals, Inc. (RXRX) and Board Member at Pacific Biosciences Of California, Inc. (PACB) since January 1, 2026. The newest filing on record that lists Chris Gibson as Board Member at Pacific Biosciences Of California, Inc. (PACB) is dated April 23, 2026. Recursion Pharmaceuticals, Inc. reported in an 8-K filed August 8, 2024 that Chris Gibson was appointed CEO of the combined company. Chris Gibson has spoken on 4 earnings calls across 1 company, most recently for Recursion Pharmaceuticals, Inc. on May 5, 2025. Recursion Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Pacific Biosciences Of California, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Recursion Pharmaceuticals, Inc. includes Christopher C. Gibson (CEO and Board Member), Najat Khan (CEO), Najat Khan, Ph.D. (CEO and Board Member) and 7 others.
“Chris Gibson, Ph.D., Co-Founder & CEO of Recursion, will serve as CEO of the combined company”
“We're going to go ahead and get started. Perfect. So, of course, it's important to note that we're going to be providing forward-looking information today, so please understand all of these important caveats.”
“And I'm joined by our Chief R&D and Commercial Officer, Najat Khan, and the Interim CEO and I hope very soon to be CSO of Recursion, Interim CEO of Exscientia and soon to be CSO of Recursion, Dave Hallett.”
“I want to share some exciting updates from the company over the last quarter as we strive to achieve our mission of decoding biology to significantly enhance lives.”
“You may wonder what a learnings call is and why we are implementing this practice now. Traditional earnings calls have value, but over the years, they've often become overly scripted, rather dull, and difficult for stakeholders to engage with.”
2026-01-01–present
Last confirmed April 23, 2026
Biotechnology · Healthcare
CEO
Medical Devices · Healthcare
Board Member
2026-01-01–present
